Tóth, G., Szöllősi, J., Abken, H., Vereb, G., Szöőr, Á.: A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Int. J. Mol. Sci. 21 (3), 1-11, 2020.

Szöőr, Á., Tóth, G., Zsebik, B., Szabó, V., Eshhar, Z., Abken, H., Vereb, G.: Trastuzumab Derived HER2-specific CARs for the Treatment of Trastuzumab-Resistant Breast Cancer: CAR T Cells Penetrate and Eradicate Tumors That Are Not Accessible to Antibodies.
Cancer Lett. 484 1-8, 2020.

Tóth, G., Szöllősi, J., Vereb, G.: Quantitating ADCC against adherent cells: impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Cytom. Part A. 91 (10), 1021-1029, 2017.

Szöőr, Á., Ujlaky-Nagy, L., Tóth, G., Szöllősi, J., Vereb, G.: Cell confluence induces switching from proliferation to migratory signaling by site-selective phosphorylation of PDGF receptors on lipid raft platforms.
Cell. Signal. 28 (2), 81-93, 2016.

Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllősi, J., Vereb, G.: The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
mAbs. 8 (7), 1361-1370, 2016.

Roszik, J., Tóth, G., Szöllősi, J., Vereb, G.: Validating pharmacological disruption of protein-protein interactions by acceptor photobleaching FRET imaging.
In: Target Identification and Validation in Drug Discovery. Eds.: Jürgen Moll, Riccardo Colombo, Humana Press, Totowa, NJ, 165-78, 2013. ISBN: 9781627033107